PDS Biotechnology Corp Cash and Cash Equivalents, Fair Value Disclosure
PDS Biotechnology Corp (PDSB) had Cash and Cash Equivalents, Fair Value Disclosure of $5.60 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $5.60M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $21.66M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $26.71M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $26.20M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure | Cash and Cash Equivalents, Fair Value Disclosure as first filed |
|---|---|---|
| 2026-06-30 | $5.60M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $21.66M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $26.71M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $26.20M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $31.87M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $39.98M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $41.69M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $49.75M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $57.73M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $66.63M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $56.56M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $54.25M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $60.62M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $65.20M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $73.82M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $71.64M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $52.98M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $58.88M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $65.24M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $69.74M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $74.75M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $25.04M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $28.84M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $33.47M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $16.93M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $21.04M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $12.16M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $17.41M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $21.73M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $26.59M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $103.69K 10-K · filed 2020-03-27 | $34.65M 10-K · filed 2019-02-21 |
| 2018-09-30 | $36.81M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $45.98M 10-Q · filed 2018-08-01 | |
| 2018-03-31 | $75.00M 10-Q · filed 2018-05-01 | |
| 2017-12-31 | $88.07M 10-K · filed 2019-02-21 | |
| 2017-09-30 | $97.31M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $108.71M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $95.59M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $106.40M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $112.78M 10-Q · filed 2016-11-01 | |
| 2016-06-30 | $111.02M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $119.94M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $130.19M 10-K · filed 2017-03-02 | |
| 2015-09-30 | $52.88M 10-Q · filed 2015-11-06 | |
| 2014-12-31 | $13.73M 10-K · filed 2016-03-08 | |
| 2013-12-31 | $7.86M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |